论文部分内容阅读
目的:研究地西他滨(DAC)和阿糖胞苷(Ara-C)单用或联合作用对人急性髓细胞白血病HL60细胞增殖的影响,并探讨最佳的联合给药方式。方法:将不同浓度的DAC和Ara-C分别单独或联合作用于HL60细胞,采用CCK8法检测2种药物单独或联合作用对HL60细胞增殖的影响,采用金(正均)氏公式计算协同系数Q值分析两药的协同作用。结果:DAC和Ara-C单独作用时对HL60细胞增殖的抑制作用均呈剂量依赖关系,DAC(0.13~2.00μmol/L)序贯Ara-C联用对HL60细胞增殖抑制有协同作用(Q值为1.20~1.54),并呈剂量依赖性。DAC同时联合Ara-C或Ara-C序贯DAC无协同作用,甚至为拮抗作用(Q值<1.15)。且DAC序贯Ara-C对HL60细胞的增殖抑制率明显高于DAC同时联合Ara-C或Ara-C序贯DAC(P<0.05)。结论:DAC序贯Ara-C可协同抑制HL60细胞增殖,该方案明显优于DAC与Ara-C同时用药组或Ara-C序贯DAC组。DAC48h后序贯Ara-C联合方案在急性髓细胞白血病的治疗中可能具有重要临床意义。
OBJECTIVE: To study the effects of decitabine (DAC) and cytarabine (Ara-C) on the proliferation of human acute myeloid leukemia HL60 cells, and to explore the optimal combination mode. Methods: The effects of different concentrations of DAC and Ara-C on HL60 cells separately or in combination, CCK8 assay was used to detect the effects of two drugs alone or in combination on the proliferation of HL60 cells. The synergistic coefficient Q Value analysis of the synergy between the two drugs. Results: The inhibitory effects of DAC and Ara-C on the proliferation of HL60 cells in a dose-dependent manner. DAC (0.13-2.00μmol / L) and sequential Ara-C combined treatment had synergistic effects on the proliferation inhibition of HL60 cells (Q value 1.20 ~ 1.54), and in a dose-dependent manner. DAC at the same time combined Ara-C or Ara-C sequential DAC no synergistic effect, and even antagonistic (Q value <1.15). The inhibitory effect of sequential Ara-C on HL60 cell proliferation was significantly higher than that of DAC combined with Ara-C or Ara-C sequential DAC (P <0.05). Conclusion: Sequential Ara-C with DAC can inhibit the proliferation of HL60 cells in a dose-dependent manner. This protocol is significantly better than the DAC-Ara-C or DAC-treated group. The sequential Ara-C regimen after 48 hours of DAC may have important clinical implications in the treatment of acute myeloid leukemia.